PioglitazoneHmm… We’d better think about this again. Pioglitazone is not a good first‑line choice because it causes weight gain and fluid retention and it lacks clear cardiovascular outcome benefits. If a thiazolidinedione is considered at all, it is considered in cases where first line drugs are not indicated or unavailable, or in combination with other first line drugs. Try to think about other drugs with favourable weight and cardiovascular profiles. Always consider the full clinical context when prescribing medications and try again! |
Map: Michael Green_GEMD (1114)
|
||
|
Review your pathway |